Back to today’s briefing

Story perspectives

GLP-1 Drug Market Booms Amid Patient Access Challenges

7/7/2025

50 11

Summary

Story summary

The GLP-1 drug market is heating up, dominated by Novo Nordisk and Eli Lilly. Yet, patients face hurdles like high dropout rates, troubling side effects such as pancreatitis, and restrictive insurance coverage from providers like Blue Cross Blue Shield. These challenges threaten access to vital treatments for many in the U.S.

1 of 1

Story summary

The GLP-1 drug market is heating up, dominated by Novo Nordisk and Eli Lilly. Yet, patients face hurdles like high dropout rates, troubling side effects such as pancreatitis, and restrictive insurance coverage from providers like Blue Cross Blue Shield. These challenges threaten access to vital treatments for many in the U.S.